The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
accepted:
20
04
2021
pubmed:
11
5
2021
medline:
19
1
2022
entrez:
10
5
2021
Statut:
ppublish
Résumé
Preclinical and clinical data indicate that p53 expression might modulate the activity of the epidermal growth factor receptor (EGFR), influencing response/resistance to anti-EGFR monoclonal antibodies. However, the association between p53 status and clinical outcome has not been clarified yet. In our study, we evaluated the role of p53 expression in patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) receiving irinotecan/cetuximab in an exploratory and a validation cohort. p53 expression was analysed in patients with RAS/BRAF wild-type mCRC receiving second-line or third-line irinotecan/cetuximab. Survival distribution was assessed by the Kaplan-Meier method, while the log-rank test was used for survival comparison. Among 120 patients with RAS/BRAF wild-type mCRC included in our analysis, 52 (59%) and 19 (59%) patients showed p53 overexpression in the exploratory and validation cohort, respectively. In the exploratory cohort, low p53 expression was correlated with better median progression-free survival (hazard ratio 0.39; p < 0.0001), median overall survival (hazard ratio: 0.23; p < 0.0001) and response rate (p < 0.0001). These results were confirmed by data of the validation cohort where we observed better median progression-free survival (hazard ratio: 0.48; p = 0.0399), median overall survival (hazard ratio: 0.26; p = 0.0027) and response rate (p =0.0007) in patients with p53 normal expression mCRC. In our study, p53 overexpression was associated with anti-EGFR treatment resistance in patients with RAS/BRAF WT mCRC, as confirmed in a validation cohort. Larger studies are needed to validate the role of p53 and investigate EGFR cross-talk in these patients.
Sections du résumé
BACKGROUND
Preclinical and clinical data indicate that p53 expression might modulate the activity of the epidermal growth factor receptor (EGFR), influencing response/resistance to anti-EGFR monoclonal antibodies. However, the association between p53 status and clinical outcome has not been clarified yet.
OBJECTIVE
In our study, we evaluated the role of p53 expression in patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) receiving irinotecan/cetuximab in an exploratory and a validation cohort.
PATIENTS AND METHODS
p53 expression was analysed in patients with RAS/BRAF wild-type mCRC receiving second-line or third-line irinotecan/cetuximab. Survival distribution was assessed by the Kaplan-Meier method, while the log-rank test was used for survival comparison.
RESULTS
Among 120 patients with RAS/BRAF wild-type mCRC included in our analysis, 52 (59%) and 19 (59%) patients showed p53 overexpression in the exploratory and validation cohort, respectively. In the exploratory cohort, low p53 expression was correlated with better median progression-free survival (hazard ratio 0.39; p < 0.0001), median overall survival (hazard ratio: 0.23; p < 0.0001) and response rate (p < 0.0001). These results were confirmed by data of the validation cohort where we observed better median progression-free survival (hazard ratio: 0.48; p = 0.0399), median overall survival (hazard ratio: 0.26; p = 0.0027) and response rate (p =0.0007) in patients with p53 normal expression mCRC.
CONCLUSIONS
In our study, p53 overexpression was associated with anti-EGFR treatment resistance in patients with RAS/BRAF WT mCRC, as confirmed in a validation cohort. Larger studies are needed to validate the role of p53 and investigate EGFR cross-talk in these patients.
Identifiants
pubmed: 33970400
doi: 10.1007/s11523-021-00816-3
pii: 10.1007/s11523-021-00816-3
pmc: PMC8266772
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Irinotecan
7673326042
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-527Références
Front Oncol. 2013 Mar 04;3:43
pubmed: 23459853
Ann Oncol. 2010 Apr;21(4):683-691
pubmed: 19713247
Oncotarget. 2017 Jan 17;8(3):3980-4000
pubmed: 28002810
Nature. 2006 Jan 19;439(7074):358-62
pubmed: 16273091
J Urol. 2003 Apr;169(4):1219-28
pubmed: 12629332
Cell Cycle. 2012 Jul 15;11(14):2581-2
pubmed: 22751437
World J Gastroenterol. 2015 Jan 7;21(1):84-93
pubmed: 25574081
Biochim Biophys Acta. 2006 Aug;1766(1):120-39
pubmed: 16889899
Cancer Res. 1998 Mar 15;58(6):1149-58
pubmed: 9515799
J Clin Oncol. 2008 Dec 10;26(35):5705-12
pubmed: 19001320
Cell. 1997 Feb 7;88(3):323-31
pubmed: 9039259
Cancer Discov. 2011 Nov;1(6):508-23
pubmed: 22586653
Anticancer Res. 2009 Feb;29(2):785-91
pubmed: 19331236
Oncogene. 2010 Feb 18;29(7):949-56
pubmed: 19881536
Br J Cancer. 2011 May 24;104(11):1786-90
pubmed: 21559018
Nat Rev Clin Oncol. 2015 Oct;12(10):607-19
pubmed: 26215044
Future Oncol. 2020 Jan;16(2):4337-4339
pubmed: 31793396
J Clin Oncol. 1999 Feb;17(2):593-9
pubmed: 10080604
Oncologist. 2011;16(1):53-60
pubmed: 21212430
Cancer Biol Ther. 2013 Aug;14(8):703-10
pubmed: 23792568
Mol Cell Biol. 1996 Nov;16(11):6009-19
pubmed: 8887630
Sci Rep. 2015 Nov 06;5:16082
pubmed: 26542452
Cancer Res. 2011 Nov 15;71(22):7071-9
pubmed: 22068033
Nat Rev Cancer. 2012 Jan 24;12(2):89-103
pubmed: 22270953
Nat Rev Cancer. 2003 Jun;3(6):453-8
pubmed: 12778135
Lancet Oncol. 2016 Jun;17(6):738-746
pubmed: 27108243
Anticancer Res. 1996 Mar-Apr;16(2):951-7
pubmed: 8687158
Expert Opin Investig Drugs. 2015;24(9):1185-98
pubmed: 26044119
ESMO Open. 2017 Apr 12;2(1):e000147
pubmed: 28761730
Br J Cancer. 2017 Jul 25;117(3):315-321
pubmed: 28632725
Asian Pac J Cancer Prev. 2014;15(19):8069-73
pubmed: 25338986
Oncotarget. 2017 Jan 31;8(5):8921-8946
pubmed: 27888811
Cancer Invest. 2009 Mar;27(3):273-85
pubmed: 19194827
J Biol Chem. 1988 Apr 25;263(12):5693-9
pubmed: 2833511
Anal Quant Cytol Histol. 2006 Apr;28(2):61-8
pubmed: 16637508
J Clin Oncol. 2009 Jun 1;27(16):2622-9
pubmed: 19398573
Cold Spring Harb Perspect Biol. 2010 Dec;2(12):a000893
pubmed: 20463001
J Gastroenterol. 2006 Mar;41(3):185-92
pubmed: 16699851
Br J Cancer. 2007 Jul 2;97(1):92-7
pubmed: 17579627
Nat Cell Biol. 2013 Jan;15(1):2-8
pubmed: 23263379
Cell Cycle. 2007 May 2;6(9):1006-10
pubmed: 17457049
Cancers (Basel). 2020 May 13;12(5):
pubmed: 32413973
Hum Exp Toxicol. 2016 May;35(5):526-43
pubmed: 26183715
J Oral Pathol Med. 2012 Aug;41(7):559-67
pubmed: 22417132
Oncogene. 1994 May;9(5):1341-9
pubmed: 8152794
Cancer. 1999 Jun 15;85(12):2541-8
pubmed: 10375100
Exp Cell Res. 2003 Mar 10;284(1):54-65
pubmed: 12648465
Anal Quant Cytol Histol. 2011 Aug;33(4):196-204
pubmed: 21980623
J Natl Cancer Inst. 2015 Sep 23;107(12):djv258
pubmed: 26405092
Nat Rev Immunol. 2006 Apr;6(4):261-70
pubmed: 16498454
Nature. 1992 Jul 2;358(6381):15-6
pubmed: 1614522
Cancer Res. 2000 Dec 15;60(24):6788-93
pubmed: 11156366
J Biol Chem. 1988 May 5;263(13):6329-36
pubmed: 3283124
Clin Cancer Res. 2004 Jan 15;10(2):784-93
pubmed: 14760102
Expert Rev Mol Diagn. 2018 Jun;18(6):499-512
pubmed: 29708446
Semin Cancer Biol. 2003 Feb;13(1):49-58
pubmed: 12507556
J Transl Med. 2012 Apr 10;10:71
pubmed: 22490361
Br J Cancer. 2004 Oct 18;91(8):1415-9
pubmed: 15452548
Oncologist. 2019 Oct;24(10):1395-1402
pubmed: 30952821
Ann Oncol. 2012 Jul;23(7):1706-12
pubmed: 22112971
Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8
pubmed: 11597398
Clin Med Oncol. 2008;2:47-61
pubmed: 21892266
Int J Cancer. 2010 Oct 15;127(8):1941-7
pubmed: 20099280
Curr Drug Targets. 2014;15(13):1225-30
pubmed: 25382208
Oncogene. 2008 Jul 17;27(31):4315-23
pubmed: 18391986
BMC Cancer. 2009 Aug 27;9:303
pubmed: 19712476
J Pathol. 1994 Jan;172(1):5-12
pubmed: 7931827
Transl Oncol. 2010 Feb;3(1):1-12
pubmed: 20165689
Br J Cancer. 2009 Apr 21;100(8):1330-5
pubmed: 19367287
Genes Dev. 1996 May 1;10(9):1054-72
pubmed: 8654922
Curr Opin Genet Dev. 2002 Feb;12(1):53-9
pubmed: 11790555
Cancer Biol Ther. 2015;16(9):1269-80
pubmed: 26177827
J Pathol. 2016 Mar;238(4):562-70
pubmed: 26690310
Expert Opin Ther Targets. 2006 Apr;10(2):281-7
pubmed: 16548776
Curr Opin Oncol. 2002 Jan;14(1):86-91
pubmed: 11790986
Cancer Res. 2007 Jun 15;67(12):5667-72
pubmed: 17575133
J Clin Oncol. 2014 Sep 20;32(27):2940-50
pubmed: 25154822
Eur J Surg Oncol. 1999 Jun;25(3):297-301
pubmed: 10336811
Pharmacogenomics. 2014 Sep;15(13):1701-15
pubmed: 25410895
Mol Cell Biol. 2000 May;20(9):3224-33
pubmed: 10757806
Exp Cell Res. 2003 Mar 10;284(1):66-77
pubmed: 12648466
Clin Cancer Res. 2017 May 1;23(9):2195-2202
pubmed: 27780855
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Cell. 1989 Dec 1;59(5):815-25
pubmed: 2556218
Curr Pharm Des. 2012;18(30):4668-78
pubmed: 22650254
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544